Peripheral blood stem cell transplantation for the treatment of multiple myeloma: Biological and clinical implications

Haematologica

Volumn 81, Issue 4, 1996, Pages 356-375

  Cappio, Federico Caligaris ^b   Cavo, Michele ^b   De Vincentiis, Armando ^b   Lanuta, Luigi ^b   Lemoli, Roberto Massimo ^b   Majolino, Ignazio ^b   Tarella, Corrado ^b   Zanon, Paola ^b   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS BONE MARROW TRANSPLANTATION; B LYMPHOCYTE; CARCINOGENESIS; HUMAN; MULTIPLE MYELOMA; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA;

EID: 0030326374     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (177)

1. Herrinton LJ, Weiss NS, Olshan AF. The epidemiology of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, eds. Myeloma, biology and management, Oxford:Oxford Medical Publ, 1995:127-68.
2. Turesson I, Zettervall O, Cuzick J, Waldenström JB, Velez R. Comparison of trends in the incidence of multiple myeloma in Malmo, Sweden and other countries. N Engl J Med 1984; 310:421-4.
3. Obrams GI, Potter M. Epidemiology and biology of multiple myeloma. Berlin:Springer-Verlag, 1991.
4. Evaluating the National Cancer Program: an ongoing process. National Cancer Institute, Bethesda, Md, USA, 1994.
5. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin N Am 1992; 6:225-47.
6. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogen 1995; 82:41-9.
7. Zandecki M, Obein V, Bernardi F, et al. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol 1995; 90:693-6.
8. Drach J, Angerler J, Schuster I, et al. Interphase fluorescence in situ identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995; 86:3915-21.
9. th ed. New York: 1995: 1109-26.
10. Hoover RG, Kornbluth J. Immunoregulation of murine and human myeloma. Hematol Oncol Clin N Am 1992; 6:407-24.
11. Potter M. Myeloma proteins (M-components) with antibody-like activity. N Engl J Med 1971; 284:831-8.
12. Seligmann M, Brouet JC. Antibody activity of human myeloma globulins. Semin Hematol 1973; 10:163-77.
13. Konrad RJ, Kricka LJ, Goodman DBP, Goldman J, Silberstein LE. Myeloma-associated paraprotein directed against the HIV-1 p24 antigen in an HIV-1-seropositive patient. N Engl J Med 1993; 328:1817-9.
14. Bakkus MHC, Heirman C, Van Riet I, Van Camp B, Thidemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80:2326-35.
15. Vescio RA, Cao J, Hong CH, et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol 1995; 155:2487-97.
16. Kelsoe G. B cell diversification and differentiation in the periphery. J Exp Med 1994; 180:5-6.
17. Caligaris-Cappio F, Gregoretti MG. Basic concepts: plasma cells in multiple myeloma. In: BGM Durie, G. Gahrton, eds. Multiple Myeloma. London: E. Arnold Publisher, in press.
18. Benner R, Hijmans W, Haajman JJ. The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation. Clin Exp Immunol 1981; 46:1-8.
19. DiLosa RM, Maeda K, Masuda A, Szakal AK, Tew JG. Germinal center B cells and antibody production in the bone marrow. J Immunol 1991; 146:4071-7.
20. Liu YJ, Johnson GD, Gordon J, MacLennan ICM. Germinal centres in T-cell dependent antibody responses. Immunol Today 1992; 13:17-21.
21. MacLennan ICM. In which cells does neoplastic transformation occur in myelomatosis? Curr Top Microbiol Immunol 1992; 182:209-13.
22. Caligaris-Cappio F, Gregoretti MG, Ghia P, Bergui L. In vitro growth of human multiple myeloma: implications for biology and therapy. Hematol Oncol Clin N 1992; 6:257-71.
23. Corradini P, Boccadoro M, Voena C, Pileri A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cm sequence in IgG and IgA secreting multiple myelomas. J Exp Med 1993; 178:1091-6.
24. Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993; 178:1023-31.
25. Rolink A, Melchers F. Generation and regeneration of cells of the B-lymphocyte lineage. Curr Opin Immunol 1993; 5:207-17.
26. Kinkade P, Lee G, Pietrangeli CE, Hayashi SH, Gimble J. Cells and molecules that regulate B lymphopoiesis in bone marrow. Annu Rev Immunol 1989; 7:111-43.
27. Degrassi A, Hilbert DM, Rudikoff S, Anderson AO, Potter M, Coon HG. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Natl Acad Sci USA 1993; 90:2060-4.
28. Caligaris-Cappio F, Bergui L, Gregoretti MG, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77:2688-93.
29. Thiery JP, Boyer B. The junction between cytokines and cell adhesion. Current Opin Cell Biol 1992; 4:782-92.
30. Hynes RO. Integrins: versatility, modulation and signalling in cell adhesion. Cell 1992; 69:11-25.
31. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73:517-26.
32. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85:863-72.
33. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86:1243-54.
34. Jernberg H, Pettersson M, Kishimoto T, Nilsson K. Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines. Leukemia 1991; 5:255-65.
35. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84:2008-11.
36. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78:1198-204.
37. Bataille R, Chappard D, Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin N Am 1992; 6:285-95.
38. Bersagel DE. The role of chemotherapy in the treatment of multiple myeloma. Baillière's Clin Haematol 1995; 8:783-94.
39. Gregory WN, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10:334-42.
40. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 1983; 1:822-4.
41. Barlogie B, Hall R, Znader A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67:1298-301.
42. Selby PJ, McElwain TJ, Nandi AC, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66:55-62.
43. Cavo M, Benni M, Gozzetti A, et al. The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma. Baillière's Clin Haematol 1995; 8:795-813.
44. Barlogie B, Alexanian R, Dicke KA, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70:869-72.
45. Jagannath S, Barlogie B, Dicke K, et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990; 76:1860-6.
46. Harosseuau JL, Milpied N, LaPorte JP, et al. Double-intensive therapy in high-risk multiple myeloma. Blood 1992; 79: 2827-33.
47. Altai M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79:1130-6.
48. Cunningham D, Paz-Arez L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12:759-63.
49. Altai M, Harousseau JL, Stoppa AM, et al. High dose therapy in multiple myeloma: final analysis of a prospective randomized study of the "Intergroupe Français du Myelome" (IFM 90). Blood 1995; 86 (suppl. 1): Abstract no 485.
50. Björkstrand B, Goldstone AH, Ljungman P, et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: An EBMT registry study. Leuk Lymphoma 1994; 15:265-72.
51. Barlogie B, Jagannath S, Vesole D, et al. Autologous and allogeneic transplants for multiple myeloma. Semin Hematol 1995; 32:31-44.
52. Harousseau JL, Altal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 1995; 85:3077-85.
53. Vesole DH, Barlogie B, Jagannath S et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84:950-6.
54. Gore ME, Selby PJ, Viner C, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; 2:879-81.
55. Dimopoulos MA, Alexanian R, Przepiorka D, et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82:2324-8.
56. Fermand JP, Chevret S, Ravaud P, et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993; 82:2005-9.
57. Alegre A, Lamana M, Arranz R, et al. Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 1995; 91:380-6.
58. Barlogie B, Iagannath S, Dixon DO, et al. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 1990; 76:677-80.
59. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favourable variables for rapid engraftment in 225 patients. Blood 1995; 85:588-96.
60. Cavo M, Benni M, Cirio TM, et al. Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published trials. Stem Cells 1995; 13 (suppl. 2): 121-6.
61. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87:1196-8.
62. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet 1996; 347:800-1.
63. Joshua DE, Gibson J, Brown RD. Mechanisms of the escape phase of myeloma. Blood Rev 1994; 8:13-20.
64. Alexanian R, Dimopoulos M, Smith T, et al. Limited value of myeloablative therapy for late multiple myeloma. Blood 1994; 83:512-6.
65. Alexanian R, Dimopoulos MA, Smith T, et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84:4278-82.
66. + peripheral bood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86:390-7.
67. + cells to remove circulating tumour cells. Blood 1996; 87:1625-34.
68. Cunningham D, Powles R, Viner C, et al. High-dose chemotherapy and autologous bone marrow transplantation in multiple myeloma. Abstract Book IV International Workshop on Multiple Myeloma (Rochester) 1993; p. 102.
69. Corradini P, Voena C, Astolfi M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85:1596-602.
70. Gianni AM, Bregni M, Siena S, et al. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high-dose chemotherapy? Hematol Oncol 1989; 7:139-48.
71. Gianni AM, Bregni M, Siena S, et al. Granulocyte-macrophage colony stimulating factor to harvest circulating hemopoietic stem cells for autotransplantation. Lancet 1989; 2:580-5.
72. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high dose therapy for malignancies. Blood 1991; 77:211-2.
73. Sheridan WP, Begley CG, Juttner C, et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 1992; 1:640-4.
74. Tarella C, Ferrero D, Bregni M, et al. Peripheral blood expansion of early progenitor cells after high dose cyclophosphamide and rhGM-CSF. Eur J Cancer 1991; 27:22-7.
75. Haas R, Ho AD, Bredthauer U, et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte macrophage colony-stimulating factor. Exp Hematol 1990; 18:94-8.
76. Shimazaki C, Oku N, Ashihara E, et al. Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 1992; 10:341-6.
77. Teshima T, Harada M, Takamatsu Y, et al. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant 1992; 10:215-20.
78. Brugger W, Birken R, Bertz H, et al. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br J Haematol 1993; 84:402-7.
79. Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1992; 77:400-9.
80. Siena S, Bregni M, Brando B, et al. Practical aspects of flow cytometry to guide large-scale collection of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Int J Cell Cloning 1992; 10:26-9.
81. Siena S, Bregni M, Di Nicola M, et al. Durability of hematopoiesis following myeloablative cancer therapy and autografting with peripheral blood hematopoietic progenitors. Ann Oncol 1994; 5:935-41.
82. Ravagnani F, Siena S, Bregni M, Sciorelli G, Gianni AM, Pellegris G. Large cell collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer 1990; 26:562-4.
83. Tong I, Hoffman R, Siena S, et al. Characterization and quantitation of primitive hemopoietic progenitor cells present in peripheral blood autografts. Exp Hematol 1994; 21:1016-24.
84. + cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens. Bone Marrow Transplant 1994; 13:479-85.
85. Pettengell R, Luft T, Henschler R, et al. Direct comparison by limiting dilution analysis of long-term culture-initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 1994; 84:3653-9.
86. Gianni AM, Tarella C, Siena S, et al. Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. Bone Marrow Transplant 1990; 6:143-5.
87. Johnsen HE, Hansen PB, Plesner T, et al. Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor. Bone Marrow Transplant 1992; 10:229-34.
88. Janssen WE. Peripheral blood and bone marrow hematopoietic stem cells: are they the same? Semin Oncol 1993; 20 (suppl.6):19-27.
89. Eaves CJ. Peripheral blood stem cells reach new heights. Blood 1993; 82:1957-9.
90. Tarella C, Benedetti G, Caracciolo D, et al. Both early and committed haematopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. Br J Haematol 1995; 91:535-43.
91. Reiffers J, Marit G, Boiron JM. Autologous blood stem cell transplantation in high-risk multiple myeloma. Br J Haematol 1989; 72:296-7.
92. Pileri A, Tarella C, Bregni M, et al. GM-CSF exposed peripheral blood progenitors as sole source of stem cells for autologous transplantation in two patients with multiple myeloma. Haematologica 1990; 75:79-82.
93. Barlogie B, Alexanian R, Smallwood L, et al. Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood 1988; 72:2015-9.
94. Lokhorst HM, Meuwissen OJA, Verdonk LF, Dekker A. High-risk multiple myeloma treated with high-dose melphalan. J Clin Oncol 1992; 10:47-51.
95. Cunningham D, Paz-Ares L, Gore ME, et al. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol 1994; 12:764-8.
96. Mansi J, da Costa F, Viner C, Judson I, Gore ME, Cunningham D. High-dose busulfan in patients with myeloma. J Clin Oncol 1992; 10:1569-73.
97. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80:1666-72.
98. Gianni AM, Tarella C, Bregni M, et al. High-dose sequential (HDS) chemo-radiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 1994; 12:503-9.
99. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995; 16:7-11.
100. Wunder E. Stimulation of granulocyte macrophage progenitors via monocyte/macrophage activation: a fundamental regulatory pathway of terminal differentiation. In: Wunder EW, Henon PR, eds. Peripheral blood stem cell autografts. Berlin:Springer-Verlag, 1993:58-66.
101. Mauch P, Ferrara J, Hellman S. Stem cell self-renewal considerations in bone marrow transplantation. Bone Marrow Transplant 1989; 4:601-7.
102. Kotasek D, Sheperd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9:11-7.
103. Haas R, Möhle R, Fruehauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83:3787-94.
104. Schneider JG, Crown JP, Wasserheit C, et al. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients. Bone Marrow Transplant 1994; 14:877-84.
105. Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87:825-31.
106. Laporte JP, Gorin NC, Dupuy-Montbrun MC, et al. Failure to collect sufficient amount of peripheral blood stem cells (PBSC) for autografting in patients with endstage multiple myeloma. Bone Marrow Transplant 1988; 3(suppl 1):89.
107. Tarella C, Caracciolo D, Gavarotti P, et al. Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization. Bone Marrow Transplant 1995; 16:223-8.
108. Tarella C, Boccadoro M, Omedé P, et al. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. Bone Marrow Transplant 1993; 11: 271-7.
109. Dimopoulos MA, Hester J, Huh Y, Champlin R, Alexanian R. Intensive therapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol 1994; 87:730-4.
110. Haas R, Möhle R, Murea S, et al. Characterization of peripheral blood progenitor cells mobilized by cytotoxic chemotherapy and recombinant human granulocyte colony-stimulating factor. J Hematother 1994; 3:323-30.
111. Ossenkoppele GJ, Ionkhoff AR, Huijgens PC, et al. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma. Bone Marrow Transplant 1994; 13:37-41.
112. Majolino I, Marceno R, Buscemi F, et al. Mobilization of circulating progenitor cells in multiple myeloma during VCAD therapy with or without rhG-CSF. Haematologica 1995; 80:108-14.
113. Vasta S, Majolino I, Morabito F, et al. The association of vincristine, cyclophosphamide, epirubicin and dexamethasone (VCED) followed by rhG-CSF may provide a good PBSC mobilization in patients with multiple myeloma. Submitted for publication.
114. Kessinger A, Armitage JO, Smith DM, et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74:1260-5.
115. Hénon P, Beck G, Debecker A, Eisenman JC, Lepers M, Kandel G. Autograft using peripheral blood stem cells collected after high-dose melphalan in high-risk multiple myeloma. Br J Haematol 1988; 70:254-5.
116. Fermand JP, Levy Y, Gerota J, et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989; 73:20-3.
117. Reiffers J, Marit G, Boiron JM. Peripheral blood stem-cell transplantation in intensive treatment of multiple myeloma. Lancet 1989; ii:1336.
118. Indovina A, Majolino I, Scimé R, et al. High dose cyclophosphamide: stem cell mobilizing capacity in 21 patients. Leuk Lymphoma 1994; 14:71-7.
119. Duhrsen V, Villeval JL, Boyd J, Kannourakis G, Moerstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72:2074-81.
120. Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81:3158-63.
121. Majolino I, Buscemi F, Scimè R, et al. Treatment of normal donors with rhG-CSF 16 μg/kg for mobilization of peripheral blood stem cells and their apheretic collection for allogeneic transplantation. Haematologica 1995; 80:219-26.
122. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; i:1194-8.
123. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into the peripheral blood of patients with solid tumors. Blood 1994; 83:636-40.
124. Gianni AM, Bregni M, Siena S, et al. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J Clin Oncol 1992; 10:1955-62.
125. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1:329-41.
126. 8/kg is sufficient to predict early multilineage engraftment in patients undergoing high dose therapy and transplantation with cryopreserved peripheral blood progenitor cells for malignant lymphoma (abstract). Blood 1994; 84 (suppl 1):364.
127. Schwartzberg L, Birch R, Blanco R, et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11:369-74.
128. Pierelli L, Iacone A, Quaglietta AM, et al. Haemopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: a multicentre retrospective study. Br J Haematol 1994; 86:70-5.
129. + cell subsets and platelet recovery after PBSC autograft. Bone Marrow Transplant, in press.
130. Schiller G, Rosen L, Vescio R, et al. Threshold dose of autologous CD34 positive peripheral blood progenitor cells required for engraftment after myeloablative treatment for multiple myeloma. Blood 1994;84 (suppl 1):207.
131. Zimmerman TM, Lee WJ, Bender JG, Mick R, Williams SF. Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transplant 1995; 9:439-44.
132. Indovina A, Majolino I, Buscemi F, et al. Engraftment kinetics and long-term stability of hematopoiesis following autografting of peripheral blood stem cells. Haematologica 1995; 80:115-22.
133. Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-9.
134. Hénon PR, Wunder E, Zingsem J, Lepers M, Siegert W, Eckstein R. Collection of peripheral blood stem cells. Apheresis monitoring and procedure. In: Wunder EW, Henon PR, eds. Peripheral blood stem cell autografts. Berlin:Springer-Verlag, 1993:185-93.
135. Buscemi F, Fabbiano F, Felice R, et al. Use of large polygonal contiguous gates for flow cytometry analysis of circulating progenitor cells. Bone Marrow Transplant 1993; 12:305.
136. Rowley S. Analysis of the collected product. In: Kessinger A, McMannis JD, eds. Practical considerations of apheresis in peripheral blood stem cell transplantation. Lakewood, Co: Cobe BCT, Inc., 1994:35-51.
137. Legros M, Fleury J, Curé H, et al. New method for stem cell quantification: applications to the management of peripheral blood stem cell transplantation. Bone Marrow Transplant 1995; 15:1-8.
138. Mijovic A, Mufti GK. Single dose of filgrastim (rhG-CSF) to predict mobilization of hemopoietic progenitors in patients with hematologic malignancies. Bone Marrow Transplant 1995; 15:813-4.
139. Fruehauf S, Haas R, Conradt C, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 1995; 85:2619-26.
140. Roberts AW, Begley CG, Grigg AP, Basser RL. Do steady-state peripheral blood progenitor cell (PBPC) counts predict the yield of PBPC mobilized by filgrastim alone? Blood 1995; 86:2451.
141. 2) for the treatment of newly diagnosed and refractory multiple myeloma patients. Submitted for publication.
142. To LB. Is our current strategy in manipulating hemopoiesis in autologous transplantation correct? Stem Cells 1993; 11: 283-9.
143. Berenson J, Wong R, Kim K, Brown N, Lichstentein A. Evidence of peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 1987; 70: 1550-3.
144. Bergui L, Schena M, Gaidano GL, Riva M, Caligaris-Cappio F. Interleukin-3 and interleukin-6 synergistically promote the proliferation and diffentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med 1989; 170:613-8.
145. Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma: a continuously differentiating possibly invasive population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin N Am 1992; 6:297-332.
146. Billadeau D, Quam L, Thomas W, et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80:1818-24.
147. Pilarski LM, Belch AR. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 1994; 83:724-36.
148. + peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995; 85: 436-47.
149. Witzig T, Kyle R, O'Fallon W, Greipp P. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol 1994; 87:266-72.
150. Grogan TM, Durie BGM, Lomen C, et al. Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features. Blood 1987; 70:932-42.
151. LeBien TW, McCormack RT. The common acute lymphoblastic leukemia antigen (CD10). Emancipation from a functional enigma. Blood 1989; 73: 625-35.
152. Pellat-Deceunyck C, Bataille R, Robillard N, et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994; 84:2597-603.
153. Witzig TE, Gertz MA, Pineda AA, Kyle RA, Greipp PR. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Br J Haematol 1995; 89:640-2.
154. Vora A, Toh C, Peel J, Greaves M. Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br J Haematol 1994; 86:180-2.
155. - Thy' stem cells do not contain clonal myeloma cells. Blood 1995; 86:381-9.
156. Gazitt Y, Tian E, Barlogie B, et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage-colony-stimulating-factor. Blood, 1996; 87:805-11.
157. Björkstrand B, Ljungman P, Bird JM, Samson D, Garthon G. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 1995; 15:367-71.
158. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341:85-6.
159. Reece DE, Barnett MJ, Connors JM. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant 1993; 11:139-46.
160. Gulati SC, Shimazaki C, Lemoli RM, Atzpodien J, Clarkson BD. Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies. Eur J Haematol 1989; 43(Suppl. 51):164-72.
161. Siena S, Castro-Malaspina H, Gulati SC, et al. Effects of in vitro purging with 4-hydroperoxycyclophosphamide on the hematopoietic and microenvironment elements of human bone marrow. Blood 1985; 65:655-62.
162. Bullock G, Tang C, Tourkina E, et al. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide induced programmed cell death or apoptosis in human myeloid leukemia cells. Exp Hematol 1993; 21:1640-4.
163. Skorski T, Kawalec M, Hoser G, Ratajczcac M, Gnatowski B, Kawiak J. The kinetic of immunologic and hematologic recovery in mice after lethal total body irradiation and reconstitution with syngeneic bone marrow cells treated or untreated with mafosphamide (Asta Z 7654). Bone Marrow Transplant 1988; 3:543-51.
164. Tong AW, Lee JC, Fay JW, Stone MJ. Elimination of clonogenic stem cells from human multiple myeloma cell lines by a plasma cell-reactive monoclonal antibody and complement. Blood 1987; 70:1482-9.
165. Anderson KC, Andersen J, Soiffer R, et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 1993; 82:2568-76.
166. Gobbi M, Cavo M, Tazzari PL, et al. Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. Eur J Haematol 1989; 43 (suppl. 51):176-81.
167. Goldmacher VS, Bourret LA, Levine BA, et al. Ami-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 1994; 84:3017-25.
168. Lemoli RM, Gobbi M, Tazzari PL, et al. Bone marrow purging for multiple myeloma by avidin-biotin immunoadsorption. Transplantation 1989; 47:385-7.
169. Carlo Stella C, Cazzola M, De Fabritiis P, et al. CD34-positive cells: biology and clinical relevance. Haematologica 1995; 80: 367-87.
170. Visani G, Lemoli RM, Dinota A, et al. Evidence that long-term bone marrow culture of patients with multiple myeloma favors normal hemopoietic proliferation. Transplantation 1989; 48:1026-31.
171. Vescio RA, Hong CH, Cao J, et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994; 84:3283-90.
172. Takishita M, Kosaka M, Goto T, Saito S. Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies. Br J Haematol 1994; 87:735-42.
173. Avvisati G, Petrucci MT, Mandelli F. The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma. Bailliere's Clinical Haematol 1995; 8:815-29.
174. Mandelli F, Awisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322:1430-4.
175. Westin J, Rodjer S, Turesson I et al. Interferon alpha-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995; 89:561-8.
176. Powels R, Cunningham D, Malpas JS, et al. A randomized trial of maintenance therapy with Intron-A following high-dose melphalan and ABMT in myeloma. Blood 1994; 84 (suppl l):535a.
177. De Laurenzi A, Iudicone P, Zoli V, et al. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects. J Hematother 1995; 4:113-20.